Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 16th December 2014
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Liberia receives ebola serum supply
Medical imagery
The serum treatment will be monitored by doctors in Liberia (stock photo)
Treatment is made from the blood of recovered survivors

Liberia has started to treat patients infected with Ebola with serum therapy - a treatment made from the blood of recovered survivors, the BBC reports.

It is hoped that the experimental treatment will help combat the virus that has been killing thousands of people throughout West Africa.

The ebola serum is made from the blood of survivors, which contain antibodies to fight off the virus. It is made by removing the red blood cells, whilst keeping the important antibodies - which can be used to treat other patients.

In the UK and US, Ebola patients have already received this form of treatment.

The serum treatment will be monitored by doctors in Liberia, who will monitor how safe and effective the therapy is.

A number of Liberian health care workers have been trained to give the serum.

Dr David Hoover, the programme's director, said: "This will empower local health care systems to become more self-sufficient and better serve their patients during this current epidemic as well as in the future."

Become a member or log in to add this story to your CPD history

Greyhound Board announces change to vaccination guidance

News Story 1
 The Greyhound Board of Great Britain has published new vaccination guidance, with all greyhounds registered from 1 January, 2027 required to have the L4 leptospirosis vaccination, rather than L2.

The change comes in response to the reduced availability of the 'L2' Leptospirosis vaccine across the UK, and aims to support best biosecurity practice across the racing greyhound population.

GBGB veterinary director Simon Gower, said "While rare, Leptospirosis is a serious infectious disease that can affect both dogs and humans, so it is vital that we offer our greyhounds the broadest possible protection.  

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.